Evidence map›Paper›PMID 32311967›Full record

ArticleMedicine2020

Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy.

Tongjuan Li, Jiaqi Tan, Liting Chen, Dong Kuang, Xia Mao, Yaoyao Lou, Jianfeng Zhou, Xiaoxi Zhou

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tongjuan LiDepartment of Hematology.
Jiaqi TanDepartment of Pediatrics.
Liting ChenDepartment of Hematology.
Dong KuangDepartment of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xia MaoDepartment of Hematology.
Yaoyao LouDepartment of Hematology.
Jianfeng ZhouDepartment of Hematology.
Xiaoxi ZhouDepartment of Hematology.
Huazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleB cell lymphoma can co-occur with multiple myeloma (MM), and the prognosis in this case is usually poor. We propose the combination of CD19-chimeric antigen receptor (CAR) T cells and BCMA-CAR T cells for the treatment of such patients to obtain a superior prognosis. PATIENT CONCERNS: We present a 50-year-old patient with previous B cell lymphoma and subsequent multiple myeloma (MM). DIAGNOSIS: A diagnosis of B cell lymphoma and MM was made.

interventionsThe patient was treated with a combination of haploidentical CD19-chimeric antigen receptor (CAR) T cells and BCMA-CAR T cells. OUTCOMES: After CAR T cell therapy, the monoclonal plasma cells in the bone marrow and M protein disappeared. LESSONS: The combination therapy of CD19- and BCMA-CAR T cells is an effective measure to treat patients with concomitant or borderline cases of B cell lymphoma and MM.

Indexed as

Immunotherapy, AdoptiveNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryAntineoplastic AgentsFemaleHumansLymphoma, B-Cell, Marginal ZoneLymphoma, Large B-Cell, DiffuseMiddle AgedMultiple MyelomaParotid NeoplasmsReceptors, Chimeric AntigenAntineoplastic AgentsReceptors, Chimeric Antigen

Identifiers

PMID32311967
PMCPMC7220358
OpenAlexW3017076804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.